Show simple item record

dc.contributor.authorWang, Qian
dc.contributor.authorHan, Jianlin ORCID
dc.contributor.authorSorochinsky, Alexander ORCID
dc.contributor.authorLanda Álvarez, Aitor ORCID
dc.contributor.authorButler, Greg
dc.contributor.authorSoloshonok, Vadim A.
dc.date.accessioned2022-08-31T08:40:41Z
dc.date.available2022-08-31T08:40:41Z
dc.date.issued2022-08-14
dc.identifier.citationPharmaceuticals 15(8) : (2022) // Article ID 999es_ES
dc.identifier.issn1424-8247
dc.identifier.urihttp://hdl.handle.net/10810/57368
dc.description.abstractNowadays, the selective introduction of fluorine into bioactive compounds is a mature strategy in the design of drugs allowing to increase efficiency, biological half-life and bio-absorption. On the other hand, amino acids (AAs) represent one of the most ubiquitious classes of naturally occurring organic compounds, which are found in over 40% of newly marked small-molecule pharmaceutical drugs and medical formulations. The primary goal of this work is to underscore two major trends in the design of modern pharmaceuticals. The first is dealing with the unique structural characteristics provided by the structure of amino acids featuring an abundance of functionality and the presence of a stereogenic center, all of which bodes well for the successful development of targeted bioactivity. The second is related to fine-tuning the desired activity and pharmacokinetics by selective introduction of fluorine. Historically, both trends were developed separately as innovative and prolific approaches in modern drug design. However, in recent decades, these approaches are clearly converging leading to an ever-increasing number of newly approved pharmaceuticals containing both structural features of amino acids and fluorine.es_ES
dc.description.sponsorshipThis work was funded by the National Natural Science Foundation of China (No. 21761132021), and IKERBASQUE, Basque Foundation for Science. The financial support from the University of the Basque Country UPV/EHU (UFIQOSYC11/22), Basque Government (GVgrant IT1236-19), and Ministerio de Ciencia e Innovación (grant PID2019-109633GBC21) for. A. L. are also acknowledged.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2019-109633GBC21es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/es/
dc.subjectpharmaceuticalses_ES
dc.subjecttailor made amino acidses_ES
dc.subjectfluorinees_ES
dc.subjectdrug designes_ES
dc.subjectasymmetric synthesises_ES
dc.titleThe Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorinees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2022-08-25T11:19:09Z
dc.rights.holder© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/15/8/999es_ES
dc.identifier.doi10.3390/ph15080999
dc.departamentoesQuímica orgánica I
dc.departamentoeuKimika organikoa I


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Except where otherwise noted, this item's license is described as © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).